0000003811 00000 n Learn about our safety approach to COVID-19 > At Bristol Myers Squibb, the work you do-often in support of emerging therapeutic areas that require new methods of thinking and working-will help people prevail over serious diseases. FDA MedWatch at 1-800-FDA-1088, and Celgene Corporation, a Bristol-Myers Squibb Company, at 1-888-423-5436. With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile., Todays news builds upon our long legacy of pioneering next-generation medicines for patients with cancer, said Samit Hirawat, M.D., Chief Medical Officer, Global Drug Development, Bristol Myers Squibb. Monthly calendar; Candle-lighting times only . Investor Relations: investor.relations@bms.com The non-GAAP financial measures are provided as supplemental information to the financial measures presented in this press release that are calculated and presented in accordance with GAAP and are presented because management has evaluated the companys financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the companys baseline performance, supplement or enhance management, analysts and investors overall understanding of the companys underlying financial performance and trends and facilitate comparisons among current, past and future periods. "Simply because we are attracting the best talent to better serve patients now, while at the same time we're focusing on developing strategic partnerships to grow our pipeline of next generation assets and deliver on our commitment to the patients of tomorrow.". Bristol-Myers Squibb bulls will hope to hear the company announce they've not only beaten. Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. Normal for industry. Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share. The Bristol-Myers Squibb Benefits Program gives you the flexibility and opportunity to choose from a variety of options. More information on suppliers is available here. 0000007516 00000 n Play. We claim: 1. Usually give off For the year end holidays too! All comparisons are made versus the same period in 2020 unless otherwise stated. If you have $1,000 at the ready, pharmaceutical stock Bristol Myers Squibb *Stock Advisor returns as of June 7, 2021. Bristol Myers Squibb is well positioned to build on our success in 2021 and continue to grow our company through the end of the decade. Headquarters Location 430 E. 29th Street 14th Floor New York, New York, 10016, United States Learn about 2023 benefits. Add to Apple Calendar. Monday Jan 11, 2021 07:30 AM ET. Operating expenses, consisting of marketing, selling and administrative expenses and research and development expenses, are expected to decrease by approximately 10% for GAAP and be in-line with 2021 levels for non-GAAP. Its good at least for California based employees. Choosing Your Medical Plan. All comparisons are made versus the same period in 2021 unless otherwise stated. Bristol ups aid. Bristol-Myers Squibb Co (BMY) Stock Price & News - Google Finance Home BMY NYSE Bristol-Myers Squibb Co Follow Share $69.30 After Hours: $69.30 (0.00%) 0.00 Closed: Mar 3, 4:02:47 PM GMT-5. Our Continuing Business, which represents in-line products and new product portfolio, is expected to grow in the low-double digits and contribute approximately $36.5 billion in 2022. endobj Bristol Myers Squibb will not tolerate practices that violate the intent of our Mission and Commitment. Privacy Protection Learn about joining our global team! 0000015083 00000 n ***Included as part of the key loss of exclusivity (LOE) brands, FOURTH QUARTER PRODUCT AND PIPELINE UPDATE, In December, the company issued its 2021 Global Access Report that detailed Bristol Myers Squibbs efforts and progress towards advancing access to healthcare and health equity globally through its own efforts and in partnership with other stakeholders. #BMSCareers. 0000042941 00000 n 0000043468 00000 n Find out why possibility lives at Bristol Myers Squibb, We demonstrate ethics, integrity and quality in everything we do for patients, customers and colleagues, We pursue disruptive and bold solutions for patients, We move together with speed and quality because patients are waiting, Our dedication to learning and excellence helps us to deliver exceptional results, We all own BMS success and strive to be transparent and deliver on our commitments, We embrace diversity and foster an environment where we can all work together at our full potential. These items are excluded from non-GAAP earnings and related EPS information because Bristol Myers Squibb believes they neither relate to the ordinary course of Bristol Myers Squibbs business nor reflect Bristol Myers Squibbs underlying business performance. We do this in a few ways: We are a culture of savers who recognize the value of saving early and often and seize the opportunities to do so. The recognition is a testament to our commitment to transform patients lives through science. These statements are only predictions, and such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. 0000042754 00000 n We are honored to be recognized by Fortune once again as one of the Worlds Most Admired Companies. 0000192949 00000 n Meet Our Team in Tampa, FL Meet Our Team in Tampa, FL Possibility Lives at BMS Find out why possibility lives at Bristol Myers Squibb Asha on Skills 2 Give Volunteer Program Asha on Skills 2 Give Volunteer Program A cash dividend payment of $0.49 per share is scheduled to be paid on November 01, 2021. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram . Posted: October 12, 2021 Full-Time At Bristol Myers Squibb, we are inspired by a single vision - transforming patients' lives through science. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram. Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2021, which reflect strong sales driven by robust commercial execution and significant advancement of the companys pipeline that further progressed the companys portfolio renewal. Learn about our safety approach to COVID-19 > At Bristol Myers Squibb, the work you do-often in support of emerging therapeutic areas that require new methods of thinking and working-will help people prevail over serious diseases. Past events. Normal for industry. (This May 18 story corrects payment value in headline and first paragraph to $1.56 billion from $1.38 billion) (Reuters) - Drugmaker Bristol Myers (NYSE: BMY) Squibb Feb 07, 2021, 01:50 AM. This earnings release and the related attachments (as well as the oral statements made with respect to information contained in this release and the attachments) contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, statements relating to goals, plans and projections regarding the companys current and projected financial position, results of operations, market position, product development, share repurchase program and business strategy. Learn about joining our global team! After the war and into the 1960s, both Squibb and Bristol-Myers expanded their production and research of antibiotics. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We may use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Bristol Myers Squibb to Participate in the 39th Annual J.P. Morgan Healthcare Conference testtest test. No forward-looking statement can be guaranteed, including that the companys future clinical studies will support the data described in this release, product candidates will receive necessary clinical and manufacturing regulatory approvals, pipeline products will prove to be commercially successful, clinical and manufacturing regulatory approvals will be sought or obtained within currently expected timeframes or contractual milestones will be achieved. Major Holidays. Available to US-based employeesChange location, Comparable to many others in the same league. Yield Attractiveness B 3.27% forward dividend yield. 0000011122 00000 n The companys lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram. (EPS) for full-year 2021 between $3.18 and $3.38, up from its previous forecast of a range of $3.12 to $3.32. Income tax benefit was approximately $510 million despite pre-tax earnings of $1.9 billion in the quarter primarily due to the impact of internal transfers of certain intangible assets of $1.0 billion. Holiday Calendar; Earnings Calendar; A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. Year. Media: media@bms.com (link). Namely, we are not able to reliably predict the impact of specified items or currency exchange rates beyond the next twelve months. Learn about joining our global team! 1 Bristol Myers Squibb Reports First Quarter Financial Results for 2022 Reports First Quarter Revenues of $11.6 Billion, an Increase of 5% YoY; or 7% When Adjusted for Foreign Exchange Posts First Quarter Earnings Per Share of $0.59 and Non-GAAP EPS of $1.96; Includes Net Impact of ($0.10) per share for GAAP and Non-GAAP EPS Due to Acquired IPRD1 0000193438 00000 n I am ready to take up a new challenge and I would like to take this opportunity to put the knowledge and skills acquired during my career at the service of my new employer and future colleagues. rotating shift 36/48, which involves working all holidays that fall on the schedule. though we are required to work bank holidays, Paid holidays for employees are always offered, they add weeks off at times. ET on February 18, 2022 by dialing in the U.S. toll free 888-203-1112 or international +1 719-457-0820, confirmation code: 2150568. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. No forward-looking statement can be guaranteed. Recently declared a week off fro everybody between xmas and new years. Cafeteria and catering services offering healthy options. 0000010800 00000 n Kitchenettes with vending machines, free coffee and tea. 0000193195 00000 n We expect our contractors and suppliers to comply with all legal and regulatory requirements for the workplace, including health and safety, diversity and human rights. In a prespecified interim analysis, In January, the company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of, In December, the company announced two regulatory applications for, In December, the company announced new data and analyses from across its hematology portfolio (, In November, the company announced that the European Commission (EC) approved, In November, the company announced three regulatory applications for deucravacitinib have been accepted for review. If, like us, you believe in the power of science to address some of the most challenging diseases of our time, then youll fit right in as we search for the next breakthroughs in biopharma. They encouraged employees to take their vacations. Job security always hanging over your head. 0000042527 00000 n (. No additional data or studies have been requested. Many of these vary by location, such as: If you're interested in advancing your career with an innovative team, join our Talent Community to keep in touch about the latest news and opportunities that match your interests. startxref Gordon Dyal & Co., LLC is serving as the exclusive financial advisor to Bristol Myers Squibb, and Kirkland & Ellis LLP is serving as legal counsel. The benefit choices you make go into effect each January 1 (or on your date of eligibility, if later), and stay in effect through December 31, as long as you remain eligible for benefits. We are proud of our companys global commitment to Inclusion & Diversity and the meaningful steps we are taking to drive equitable advancement and outcomes for all. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Christi Shaw just announced her resignation from the position of CEO of Kite. 0000042788 00000 n There's been plenty of good news for Bristol Myers Squibb (BMY 0.13%) . (PDF), UK-CA Slavery and Human Trafficking Statement (PDF), Our Commitment to Global Inclusion & Diversity>. As a result, the reconciliation of these non-GAAP measures to the most directly comparable GAAP measures is not available without unreasonable effort. ET on February 4 through 11:30 a.m. This information is among the primary indicators that we use as a basis for evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods. Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to and are not intended to be considered in isolation or as a substitute for the related financial measures presented in the press release that are prepared in accordance with GAAP and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. Case Timeline November 12, 2021 PRESS RELEASE: FTC Approves Modifications to Bristol Meyers Squibb Divestiture Agreement January 13, 2020 File Complaint (112.81 KB) File For more information, visit www.tptherapeutics.com. 0000192879 00000 n A dds details on agreement, background. Following the successful closing of the tender offer, Bristol Myers Squibb will acquire all remaining shares of Turning Point Therapeutics that are not tendered into the tender offer through a second-step merger at the same price of $76.00 per share. 0000004307 00000 n Whether recruiting from academia or the commercial biopharma sector, Mihaela explains why a move to BMS is a great career move. Certain other significant tax items are also excluded such as the impact resulting from internal transfers due to streamlining our legal entity structure subsequent to the Celgene acquisition and the global intangible low taxed income tax change upon finalization of the Otezla* divestiture in 2020.